What TB-500 Is
TB-500 is a synthetic peptide that corresponds to the active region of Thymosin Beta-4, a 43-amino-acid protein that is one of the most abundant intracellular proteins in mammalian cells. The synthetic fragment is shorter than the full protein, reproducing the active actin-binding sequence in a form that is easier to manufacture, easier to dose, and more stable in solution than the full parent protein would be.
The full name TB-500 is the research code that has stuck in the operator and supplier vocabulary, and it is functionally interchangeable with the term Thymosin Beta-4 fragment in most educational contexts. The molecule is not the same as the full Thymosin Beta-4 protein that has gone through human clinical trials in cardiac and ophthalmic indications, and that distinction is worth keeping in mind when reading the literature.
The peptide is most commonly available as the acetate salt of the active fragment, supplied as a lyophilized powder in 2 mg or 5 mg vials. The molecule is robust in solution after reconstitution, more so than several of the smaller peptides in this category, which is part of why the storage and handling conversation around TB-500 is more forgiving than it is around some of the more fragile peptides.
Origin: From Thymic Extract to Synthetic Fragment
Thymosin Beta-4 was originally identified in the 1980s as one of the active components of thymic extract, a preparation that researchers had been studying since the 1960s for its effects on immune system development and tissue regeneration. The full protein was isolated, sequenced, and eventually characterized as a major intracellular regulator of actin polymerization, which is the cellular process at the foundation of wound healing, cell migration, and a wide range of repair sequences.
The synthetic fragment that became TB-500 was developed as a research tool and as a therapeutic candidate that could reproduce the active region of the parent protein in a form that was practical to produce at scale. The fragment carries the actin-binding sequence and the cell-migration signal, which are the two functional properties that account for most of the regenerative effects in the published literature.
The molecule has been studied in animal models for soft tissue injury, cardiac injury, dermal wound healing, and central nervous system injury. The full protein, Thymosin Beta-4, has gone further in human clinical work than the fragment has, and the two should not be confused when reading clinical trial summaries.
The Mechanism: Actin Sequestration, Cell Migration, Angiogenesis
The mechanism story for TB-500 starts with actin. Actin is the protein that forms the cellular cytoskeleton, and the regulation of actin polymerization is the central process in wound healing, cell migration, and tissue remodeling. TB-500 binds free actin monomers and sequesters them, which keeps a pool of actin available for rapid polymerization when the cell needs to migrate, change shape, or contribute to a repair sequence.
The downstream consequence of actin sequestration is increased cell migration and increased angiogenesis. Cells that are positioned to migrate into a wound bed do so more efficiently when the actin pool is well regulated, and endothelial cells that are forming new capillaries do so more efficiently for the same reason. The published animal data on accelerated wound healing, accelerated tendon and ligament repair, and accelerated cardiac tissue repair all map back to these two downstream effects.
There is also work on inflammatory modulation, on the recruitment of stem and progenitor cells to injury sites, and on extracellular matrix remodeling, all of which fold into the broader picture of a regenerative compound. The full mechanism story is broader than any single pathway, but actin regulation is the anchor that the rest of the story builds on.
The Research Landscape
The published literature on TB-500 and on its parent protein Thymosin Beta-4 spans dermal wound healing, corneal injury, cardiac infarction models, soft tissue injury, and a smaller number of central nervous system injury studies. The animal data is consistent across multiple injury models, and the parent protein has gone into human clinical trials in cardiac and ophthalmic indications with reported safety profiles that have supported continued development.
What is established in the literature: consistent acceleration of soft tissue and dermal wound healing in animal models, consistent effects on capillary formation and on cell migration in injury beds, and a clinical safety record for the parent protein in early-phase human trials. The mechanism studies have given the field a workable picture of how the molecule acts on actin and on cell migration.
What is not established in the strict regulatory sense: large-scale human efficacy trials of the synthetic fragment specifically. The clinical work that has gone furthest is on the full Thymosin Beta-4 protein, and the educational community treats the fragment as a research-grade analog with a coherent mechanism story rather than as a regulated therapeutic. The educational interest in the compound rests on the strong animal literature, the parent-protein clinical work, and the clear mechanism, not on the kind of trial data on the fragment specifically that would let anyone make medical claims.
Educational Dosing Reference
The dosing pattern that shows up most consistently in the educational literature is a loading phase followed by a maintenance phase. The loading phase is typically 2 to 2.5 mg per week for 4 to 6 weeks, often split into two subcutaneous doses per week, followed by a maintenance phase of 2 to 2.5 mg every two weeks. This is not medical advice. It is a description of where the published animal-to-human translations and the operator community have converged.
The split-dose pattern within a week, typically Monday and Thursday, comes from the half-life data and from the operator preference for keeping the systemic peptide level more even than a single weekly bolus would produce. Single weekly dosing also shows up in the literature and has its proponents, particularly for operators who are stacking TB-500 with other compounds and who want to keep the injection schedule simpler.
Subcutaneous administration is the standard route in the educational literature, and the peptide does not appear to require fasted-state administration the way some of the other peptides in this category do. The dosing math is independent of meal timing.
Reconstitution Specifics
TB-500 ships as a lyophilized powder, typically in 2 mg or 5 mg vials, and the powder needs to be reconstituted with bacteriostatic water before any of the dosing math becomes meaningful.
The standard educational reconstitution for a 5 mg vial is 2.5 mL of bacteriostatic water, which gives a concentration of 2 mg per mL. On a U-100 insulin syringe, where one full unit is 10 mcL, that means 50 units delivers 1 mg and a full 100 unit syringe delivers 2 mg. For a 2 mg vial reconstituted with 1 mL, the concentration is the same 2 mg per mL and the unit math is identical.
Some operators reconstitute the 5 mg vial with 5 mL of bacteriostatic water for a 1 mg per mL concentration, which makes the unit math even simpler at the cost of using more bacteriostatic water and ending up with a larger total volume. Both approaches are workable, and the choice between them is mostly a matter of convenience.
The reconstitution should be done by injecting the bacteriostatic water down the side of the vial, not directly onto the powder cake. After the water is added, the vial gets gentle swirling, never shaking, until the powder is fully dissolved. TB-500 is more robust in this step than the more fragile peptides in this category, but the gentle handling discipline is still the right default.
Storage and Stability
Lyophilized TB-500 is stable at room temperature for the medium term, but the educational best practice is to store the unreconstituted vial in a refrigerator and to keep it out of direct light. Once reconstituted with bacteriostatic water, the vial moves to the refrigerator immediately and stays there.
The reconstituted shelf life that shows up most often in the educational literature is 30 days at refrigerator temperature, which aligns with the bacteriostatic preservative window. TB-500 is one of the more stable peptides in this category once reconstituted, and the practical experience of operators is that it tolerates the 30-day window well as long as the vial stays cold.
For operators who are running the maintenance dose pattern with a single 2 mg dose every two weeks, a 5 mg vial reconstituted into 2.5 mL covers approximately five weeks of use at maintenance dose, which lines up reasonably well with the 30-day window. Loading-phase users will go through a vial faster.
TB-500 vs BPC-157
The TB-500 versus BPC-157 conversation is one of the most common in the educational literature on connective tissue and soft tissue repair, and the two compounds are often discussed as a pair rather than as alternatives. The two molecules are mechanistically distinct, and the educational consensus is that they are complementary rather than redundant.
BPC-157 is a fifteen-amino-acid synthetic peptide derived from a gastric protective protein. The mechanism centers on VEGF and capillary formation, on nitric oxide signaling, and on growth hormone receptor expression in connective tissue. The dosing is daily, the route is subcutaneous, and the dose range is 250 to 500 mcg per day.
TB-500 is a synthetic fragment of Thymosin Beta-4. The mechanism centers on actin sequestration, cell migration, and angiogenesis. The dosing is weekly or twice-weekly, the route is subcutaneous, and the dose range is 2 to 2.5 mg per week in the loading phase.
Operators who run the two compounds together typically dose them on the same general weekly schedule, with the BPC-157 daily and the TB-500 on the Monday and Thursday split. The two are not mixed in the same syringe. The combination shows up in protocols aimed at significant connective tissue work where the operator wants both the local repair signal that BPC-157 drives and the cell-migration signal that TB-500 drives.
Common Reasons People Do Not See Results
The most common reason operators report a flat result with TB-500 is the wrong cycle phase. The loading phase is what produces the operator-reported signal, and operators who start at maintenance dose and expect to see the loading-phase response are setting themselves up for a flat experience.
The second most common reason is dose math error. A 5 mg vial reconstituted into the wrong volume can be off by a factor of two or more on the actual delivered dose, and an operator who thinks they are loading at 2 mg per dose but is actually delivering 1 mg per dose is running the protocol at half the intended exposure.
The third reason is the wrong target. TB-500 has its strongest signal in the connective tissue and soft tissue repair contexts in the animal literature. Operators using it for goals that are far from those contexts may be working in territory where the literature is thinner and the expected signal is smaller.
The fourth reason is cycle length. The loading phase is 4 to 6 weeks for a reason, and operators who stop at 2 weeks because they have not seen a dramatic change may simply have stopped before the protocol had a chance to produce its effect.
Cycling Considerations
The educational pattern for TB-500 is the loading-then-maintenance structure described above. The loading phase produces the bulk of the operator-reported repair signal, and the maintenance phase is intended to keep the regenerative tone present without continuing the high weekly exposure that the loading phase requires.
Some operators run a loading phase, then stop entirely for a 4 to 8 week off-period to evaluate, then either re-enter loading or step down to maintenance based on what they observed. Other operators move directly from loading into maintenance and stay on maintenance for an extended period. Both patterns appear in the educational literature, and the choice between them is a matter of what the operator is trying to accomplish.
For acute injury contexts, the loading phase is typically run on the more aggressive end of the dosing range and for the longer end of the loading window, then the operator drops to maintenance once the acute repair window has closed. For chronic connective tissue work, the more standard 4 week loading phase followed by maintenance is more typical.
The Educational Framework
Everything above is educational. None of it is medical advice. THE PIVOTAL PROTOCOL Academy exists to teach operators how to think about these compounds at the same level of rigor a research scientist would think about them, which means understanding the literature, understanding the mechanisms, understanding the dosing math, and understanding where the data ends and the speculation begins.
If you are working through TB-500 for the first time, the right next step is the free Academy course, which covers reconstitution, dosing math, lab work, and the cycling framework in detail. You can join below.
Join the free Academy
Get the full peptide education library, reconstitution worksheets, lab tracking templates, and the cycling framework.